Bronchial Beta-adrenoceptor Blockade Following Eyedrops of Timolol and Its Isomer L-714,465 in Normal Subjects
Overview
Authors
Affiliations
The R-enantiomer of timolol, L-714,465, is considerably less potent as a beta 1- and beta 2-adrenoceptor antagonist in animals than timolol, whilst only slightly less potent in reducing intraocular pressure. If the same was true in man L-714,465 would have potential benefits over timolol in the treatment of glaucoma. The extent of bronchial beta-adrenoceptor blockade following one eyedrop in each eye of timolol 1% and L-714,465 1% was compared in six normal subjects, by measuring the displacement of the bronchodilator dose-response curve to isoprenaline following each drug compared to the isoprenaline dose-response curve after placebo eyedrops (methyl-cellulose). There was no significant difference between the dose-response curves to L-714,465 and placebo, but a significant displacement of the dose-response curve following timolol. The geometric mean dose ratio following timolol (21) differed significantly from that following L-714,465 (1.6). Heart rate at the end of the isoprenaline dose-response study was lower after timolol, despite the fact that subjects had received higher doses of isoprenaline. The trend was in the same direction after L-714,465 when compared with placebo though less marked. L-714,465 clearly causes less beta-adrenoceptor blockade than timolol when given as 1% eyedrops. The effects of L-714,465 1% on the airways and heart rate did not differ significantly from placebo in these six subjects but the pattern of response would be most consistent with L-714,465 having some beta-adrenoceptor blocking activity though considerably less than timolol.
Drug chirality and its clinical significance.
Hutt A, Tan S Drugs. 1996; 52 Suppl 5:1-12.
PMID: 8922553 DOI: 10.2165/00003495-199600525-00003.
Proceedings of the British Pharmacological Society. 17th-19th December 1986. Abstracts.
Br J Pharmacol. 1987; 90 Suppl:1P-292P.
PMID: 3801788 PMC: 1917253.
Richards R, Tattersfield A Br J Clin Pharmacol. 1987; 24(4):485-91.
PMID: 2961362 PMC: 1386311. DOI: 10.1111/j.1365-2125.1987.tb03202.x.
Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.
Lee E, Williams K Clin Pharmacokinet. 1990; 18(5):339-45.
PMID: 2185905 DOI: 10.2165/00003088-199018050-00001.
Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.
Lennard M Br J Clin Pharmacol. 1991; 31(6):623-5.
PMID: 1867956 PMC: 1368570. DOI: 10.1111/j.1365-2125.1991.tb05583.x.